Medivation

Medivation Inc. is focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. The Company's first compound is enzalutamide, an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within the tumor cell. Enzalutamide is used for the treatment of patients with metastatic castration-resistant prostate cancer and is being further developed* for earlier stages of prostate cancer, advanced breast cancer, and hepatocellular carcinoma.

Type
Subsidiary
Parent Company
Pfizer
HQ
San Francisco, US
Founded
2004
Medivation was founded in 2004 and is headquartered in San Francisco, US

Medivation Office Locations

Medivation has offices in San Francisco, Washington, Jersey and New York
San Francisco, US (HQ)
525 Market St

Medivation Financials and Metrics

Medivation Summary

Founding Date

2004
Medivation is a subsidiary of Pfizer

Medivation Financials

USDFY, 2013FY, 2014

EBIT

(22.2 m)281.8 m

Net Income

(42.6 m)276.5 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016

R&D expense

28.7 m45.9 m40.3 m45.4 m44.7 m47.3 m45.9 m77.6 m73.4 m

General and administrative expense

39.3 m49.7 m52.8 m63.2 m83.9 m74.7 m75.8 m96.8 m758.4 m

Operating expense total

68 m95.7 m93.1 m108.6 m128.6 m122 m121.7 m174.4 m831.8 m

EBIT

(8 m)(8.5 m)55 m91.9 m573 k53.7 m139 m8.1 m(625.6 m)
USDFY, 2013FY, 2014FY, 2015

Cash

228.8 m502.7 m225.9 m

Inventories

18 m12.3 m15.9 m

Current Assets

354 m721.9 m634.2 m

PP&E

17 m41.2 m58.1 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016

Cash

158 m241.5 m290 m321.1 m568.6 m421.2 m488.9 m317.4 m267.8 m

Current Assets

327.9 m351.8 m415.6 m550.5 m729 m723.5 m805.8 m529.5 m605.6 m

PP&E

17.1 m18 m39.7 m41.1 m42 m44.3 m49 m59.8 m61 m

Goodwill

10 m10 m10 m18.6 m18.6 m
USDFY, 2013FY, 2014FY, 2015

Net Income

(42.6 m)276.5 m244.7 m

Inventories

(4 m)301 k(4.6 m)

Accounts Payable

1.7 m

Cash From Operating Activities

(68.2 m)273.9 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2016Q2, 2016

Net Income

(45.4 m)(13.7 m)34.3 m112.2 m(3.1 m)22.7 m4.8 m(399.1 m)

Accounts Payable

3.4 m1.7 m1.7 m1.7 m(305 k)1.7 m

Cash From Operating Activities

(52.8 m)7.4 m56.5 m76.3 m57.2 m67.2 m165.7 m178.5 m

Purchases of PP&E

(6.3 m)(1.6 m)(4.5 m)(9.2 m)(956 k)(6.5 m)(9.3 m)(13.9 m)
Show all financial metrics

Medivation's Web-traffic and Trends

Medivation Company Life and Culture

You may also be interested in